 Curtis Henry
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 6 | 2025 | 1966 | 1.620 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2022 | 293 | 0.970 |
Why?
| | Leukemia | 5 | 2024 | 245 | 0.910 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 62 | 0.880 |
Why?
| | Hematopoiesis | 2 | 2017 | 194 | 0.790 |
Why?
| | Interleukin-12 | 4 | 2022 | 117 | 0.780 |
Why?
| | Dendritic Cells | 6 | 2024 | 499 | 0.780 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2023 | 101 | 0.720 |
Why?
| | Galectins | 1 | 2022 | 27 | 0.710 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 80 | 0.640 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2017 | 41 | 0.590 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 735 | 0.580 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 69 | 0.540 |
Why?
| | Models, Biological | 1 | 2025 | 1822 | 0.530 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 49 | 0.520 |
Why?
| | Interleukin-1 | 1 | 2021 | 961 | 0.500 |
Why?
| | Listeria monocytogenes | 4 | 2010 | 116 | 0.490 |
Why?
| | Folic Acid | 1 | 2017 | 199 | 0.470 |
Why?
| | Cytokines | 6 | 2023 | 2065 | 0.470 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2015 | 339 | 0.470 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 917 | 0.450 |
Why?
| | Neoplasms | 4 | 2025 | 2884 | 0.450 |
Why?
| | Listeriosis | 3 | 2010 | 65 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 167 | 0.420 |
Why?
| | Genetic Fitness | 2 | 2011 | 59 | 0.400 |
Why?
| | Interleukin-23 | 2 | 2010 | 16 | 0.390 |
Why?
| | Dietary Supplements | 1 | 2017 | 576 | 0.390 |
Why?
| | Adenoma | 1 | 2015 | 218 | 0.380 |
Why?
| | Mice | 19 | 2024 | 18365 | 0.370 |
Why?
| | Obesity | 3 | 2024 | 3082 | 0.370 |
Why?
| | Mice, Transgenic | 6 | 2021 | 2185 | 0.370 |
Why?
| | Inflammation Mediators | 1 | 2015 | 509 | 0.360 |
Why?
| | c-Mer Tyrosine Kinase | 2 | 2024 | 38 | 0.350 |
Why?
| | Animals | 22 | 2025 | 38109 | 0.340 |
Why?
| | Lymphopoiesis | 1 | 2010 | 27 | 0.330 |
Why?
| | Hematopoietic Stem Cells | 2 | 2010 | 420 | 0.320 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 89 | 0.320 |
Why?
| | Mice, Inbred BALB C | 4 | 2021 | 1253 | 0.310 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2008 | 3 | 0.290 |
Why?
| | Chemokine CCL1 | 1 | 2008 | 2 | 0.290 |
Why?
| | Chemokine CCL17 | 1 | 2008 | 5 | 0.290 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2008 | 9 | 0.290 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1322 | 0.270 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 245 | 0.260 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 848 | 0.250 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1126 | 0.240 |
Why?
| | Mice, Knockout | 4 | 2024 | 3125 | 0.240 |
Why?
| | Stem Cells | 1 | 2010 | 627 | 0.240 |
Why?
| | Mice, Inbred C57BL | 9 | 2024 | 5997 | 0.230 |
Why?
| | Mutation | 5 | 2025 | 4099 | 0.210 |
Why?
| | 5'-Nucleotidase | 1 | 2024 | 49 | 0.200 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 29 | 0.200 |
Why?
| | Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2023 | 3 | 0.200 |
Why?
| | Proteolysis | 1 | 2024 | 173 | 0.200 |
Why?
| | Adrenal Glands | 1 | 2023 | 77 | 0.190 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2024 | 230 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2022 | 56 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2023 | 103 | 0.180 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3550 | 0.170 |
Why?
| | Germ-Line Mutation | 1 | 2022 | 175 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 162 | 0.170 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2024 | 216 | 0.170 |
Why?
| | Talin | 1 | 2020 | 10 | 0.170 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 174 | 0.160 |
Why?
| | Humans | 20 | 2025 | 144957 | 0.160 |
Why?
| | Thiazines | 1 | 2020 | 13 | 0.160 |
Why?
| | Integrins | 1 | 2020 | 90 | 0.160 |
Why?
| | Sucrose | 1 | 2020 | 115 | 0.150 |
Why?
| | Disease Progression | 2 | 2025 | 2852 | 0.150 |
Why?
| | Antibodies, Bispecific | 1 | 2020 | 64 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2020 | 194 | 0.150 |
Why?
| | Bone Marrow | 2 | 2022 | 306 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 685 | 0.140 |
Why?
| | Calcineurin | 1 | 2019 | 105 | 0.140 |
Why?
| | Macrophages | 3 | 2018 | 1511 | 0.130 |
Why?
| | Inflammation | 3 | 2022 | 2880 | 0.130 |
Why?
| | Metabolism | 1 | 2017 | 44 | 0.130 |
Why?
| | Sex Factors | 1 | 2023 | 2114 | 0.130 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1982 | 0.130 |
Why?
| | Nucleotides | 1 | 2017 | 128 | 0.120 |
Why?
| | Nitriles | 1 | 2018 | 205 | 0.120 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 169 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 264 | 0.120 |
Why?
| | Inflammasomes | 1 | 2018 | 146 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2020 | 653 | 0.110 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.110 |
Why?
| | Cell Line | 1 | 2021 | 2882 | 0.110 |
Why?
| | Female | 10 | 2024 | 78376 | 0.110 |
Why?
| | Cells, Cultured | 3 | 2018 | 4155 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2020 | 870 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 475 | 0.100 |
Why?
| | Apoptosis | 1 | 2022 | 2430 | 0.100 |
Why?
| | Interferon-gamma | 2 | 2023 | 784 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 970 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2456 | 0.080 |
Why?
| | Interleukin-7 | 1 | 2010 | 65 | 0.080 |
Why?
| | Immunotherapy, Active | 1 | 2010 | 9 | 0.080 |
Why?
| | Phagosomes | 1 | 2010 | 40 | 0.080 |
Why?
| | Male | 5 | 2023 | 72406 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 294 | 0.070 |
Why?
| | Immunologic Factors | 2 | 2023 | 255 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2197 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 119 | 0.070 |
Why?
| | Immunity, Cellular | 1 | 2010 | 272 | 0.070 |
Why?
| | Immunologic Memory | 1 | 2010 | 366 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3608 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2011 | 515 | 0.060 |
Why?
| | Cell Communication | 1 | 2008 | 324 | 0.060 |
Why?
| | Up-Regulation | 1 | 2008 | 852 | 0.060 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 320 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2011 | 846 | 0.060 |
Why?
| | Immunotherapy | 2 | 2020 | 657 | 0.050 |
Why?
| | Ubiquitin-Specific Proteases | 1 | 2024 | 4 | 0.050 |
Why?
| | Cohort Studies | 1 | 2015 | 5965 | 0.050 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 81 | 0.050 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 9 | 0.050 |
Why?
| | Ubiquitination | 1 | 2024 | 118 | 0.050 |
Why?
| | Topotecan | 1 | 2023 | 17 | 0.050 |
Why?
| | Simvastatin | 1 | 2023 | 60 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 160 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2023 | 212 | 0.050 |
Why?
| | Thrombopoiesis | 1 | 2022 | 8 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2023 | 266 | 0.050 |
Why?
| | Prospective Studies | 1 | 2015 | 7997 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 1129 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 66 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2023 | 169 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 444 | 0.040 |
Why?
| | Panniculitis | 1 | 2020 | 3 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 469 | 0.040 |
Why?
| | CD3 Complex | 1 | 2020 | 111 | 0.040 |
Why?
| | Sweetening Agents | 1 | 2020 | 57 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2020 | 129 | 0.040 |
Why?
| | Tumor Escape | 1 | 2019 | 49 | 0.040 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 286 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 437 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2023 | 780 | 0.040 |
Why?
| | Polymers | 1 | 2023 | 499 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2020 | 311 | 0.040 |
Why?
| | DNA Methylation | 1 | 2024 | 683 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 883 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2020 | 902 | 0.030 |
Why?
| | Retina | 1 | 2020 | 324 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2023 | 655 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2018 | 202 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1462 | 0.030 |
Why?
| | Caspase 1 | 1 | 2018 | 148 | 0.030 |
Why?
| | Sulfones | 1 | 2018 | 127 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 389 | 0.030 |
Why?
| | Signal Transduction | 1 | 2010 | 5233 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2023 | 1167 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 235 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2018 | 395 | 0.030 |
Why?
| | Monocytes | 1 | 2018 | 538 | 0.030 |
Why?
| | RNA | 1 | 2022 | 940 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2020 | 877 | 0.030 |
Why?
| | Young Adult | 2 | 2023 | 14126 | 0.030 |
Why?
| | Aged | 1 | 2015 | 25947 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 863 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1958 | 0.020 |
Why?
| | Child | 2 | 2023 | 22657 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2020 | 2499 | 0.020 |
Why?
| | Middle Aged | 1 | 2015 | 35928 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2609 | 0.020 |
Why?
| | Succinimides | 1 | 2010 | 21 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2010 | 32 | 0.020 |
Why?
| | Fluoresceins | 1 | 2010 | 48 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 76 | 0.020 |
Why?
| | Lysosomes | 1 | 2010 | 128 | 0.020 |
Why?
| | Infant | 1 | 2023 | 10039 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2010 | 330 | 0.020 |
Why?
| | Child, Preschool | 1 | 2023 | 11799 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2007 | 157 | 0.020 |
Why?
| | DNA Damage | 1 | 2009 | 430 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2009 | 621 | 0.020 |
Why?
| | Cytosol | 1 | 2007 | 227 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2007 | 194 | 0.010 |
Why?
| | Actins | 1 | 2007 | 425 | 0.010 |
Why?
| | Adolescent | 1 | 2023 | 22453 | 0.010 |
Why?
| | Adult | 1 | 2023 | 40506 | 0.010 |
Why?
|
|
Henry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|